This paper presents some results of a joint research project conducted by FRAME and Liverpool John Moores University, and sponsored by Defra, on the status of alternatives to animal testing with regard to the European Union REACH (Registration, Evaluation and Authorisation of Chemicals) system for the safety testing and risk assessment of chemicals. The project covered all the main toxicity end-points associated with REACH. This paper focuses on the use of alternative (non-animal) methods (both in vitro and in silico) for repeat dose (sub-acute, sub-chronic and chronic) toxicity testing. It reviews the limited number of in silico and in vitro tests available for this endpoint, and outlines new technologies which could be used in the future, e.g. the use of biomarkers and the ‘omics’ technologies. An integrated testing strategy is proposed, which makes use of as much non-animal data as possible, before any essential in vivo studies are performed. Although none of the non-animal tests are currently undergoing validation, their results could help to reduce the number of animals required for testing for repeat dose toxicity.
GrindonC., CombesR., CroninM.T.D., RobertsD.W. & GarrodJ. (2006). A review of the status of alternative approaches to animal testing and the development of integrated testing strategies for assessing the toxicity of chemicals under REACH —A summary of a DEFRA-funded project conducted by Liverpool John Moores University and FRAME. ATLA34, Suppl. 1, 149–158.
2.
GrindonC., CombesR., CroninM.T.D., RobertsD.W. & GarrodJ.F. (2006). Integrated testing strategies for use in the EU REACH System. ATLA34, 407–427.
3.
CombesR.D., GrindonC., CroninM.T.D., RobertsD.W. & GarrodJ.F. (2007). Proposed integrated decision-tree testing strategies for mutagenicity and carcinogenicity in relation to the EU REACH legislation. ATLA35, 267–287.
KristensenB.W., BlaabjergM., NorabergJ. & ZimmerJ. (2007). Long-term, repeated dose in vitro neurotoxicity of the glutamate receptor antagonist L-AP3, demonstrated in rat hippocampal slice cultures by using continuous propidium iodide incubation. ATLA35, 211–221.
13.
CoeckeS., AhrH., BlaauboerB.J., BremerS., CasatiS., CastellJ., CombesR., CorviR., CrespiC.L., CunninghamM.L., ElautG., ElettiB., FreidigA., GennariA., Ghersi-EgeaJ-F., GuillouzoA., HartungT., HoetP., Ingelman-SundbergM., MunnS., JassensW., LadstetterB., LeahyD., LongA., MeneguzA., MonshouwerM., MorathS., NagelkerkeF., PelkonenO., PontiJ., PrietoP., RichertL., SabbioniE., SchaackB., SteilingW., TestaiE., VericatJ-A. & WorthA. (2006). Metabolism: A bottleneck in in vitro toxicological test development. The report and recommendations of ECVAM Workshop 54. ATLA34, 49–84.
14.
UllrichA., BergC., HengstlerJ.G. & RungeD. (2007). Use of a standardised and validated long-term human hepatocyte culture system for repetitive analyses of drugs: repeated administrations of acetaminophen reduces albumin and urea secretion. ALTEX24, 35–40.
15.
CanovaN., KmonickovaE., LincovaD., VitekL. & FarghaliH. (2004). Membrane hepatocyte bioreactor for pharmacotoxicological applications: evidence that inhibition of spontaneously produced nitric oxide improves cell functionality. ATLA32, 25–35.
16.
NakagiriR., OdaH. & KamiyaT. (2003). Small scale rat hepatocyte primary culture with applications for screening hepatoprotective substances. Bioscience, Biotechnology & Biochemistry67, 1629–1635.
17.
IsodaK., KojimaM., TakedaM., HigashiyamaS., KawaseM. & YagiK. (2004). Maintenance of hepatocyte functions by coculture with bone marrow stromal cells. Journal of Bioscience & Bioengineering97, 343–346.
18.
HanleyA.B., McBrideJ., OehlschlagerS. & OparaE. (1999). In vitro models for investigations of chronic toxicity and reversibility: use of a flow cell bioreactor as a chronic toxicity model system. Toxicology in Vitro13, 847–851.
19.
ShenC., ZhangG. & MengQ. (2007). An in vitro model for long-term hepatotoxicity testing utilizing rat hepatocytes entrapped in micro-hollow fibre reactor. Biochemical Engineering Journal34, 267–272.
20.
PazosP., FontanerS. & PrietoP. (2002). Long term in vitro toxicity models: comparisons between a flow cell bioreactor, a static cell bioreactor, and static cell cultures. ATLA30, 515–523.
21.
MinuthW.W., DermietzelR., KlothS. & HennerkesB. (1992). A new method culturing renal cells under permanent superfusion and producing a luminal basal medium gradient. Kidney International41, 215–219.
PfallerW., BallsM., ClothierR., CoeckeS., DierickxP., EkwallB., HanleyB.A., HartungT., PrietoP., RyanM.P., SchmuckG., ŠladowskiD., VericatJ-A., WendelA., WolfA. & ZimmerJ. (2001). Novel advanced in vitro methods for long-term toxicity testing. The report and recommendations of ECVAM Workshop 45. ATLA29, 393–426.
25.
DavilaJ.C., CezarG.G., ThiedeM., StromS., MikiT. & TroskoJ. (2004). Use and application of stem cells in toxicology. Toxicological Sciences79, 214–223.
26.
TahtiH., NevalaH. & ToimelaT. (2003). Refining in vitro neurotoxicity testing — The development of blood–brain barrier models. ATLA31, 273–276.
27.
BhogalN., GrindonC., CombesR. & BallsM. (2005). Toxicity testing: creating a revolution based on new technologies. Trends in Biotechnology23, 299–307.
28.
BużańskaL., HabichA., JurgaM., SypeckaJ. & Domańska-JanikK. (2005). Human cord blood-derived neural stem cell line — Possible implementation in studying neurotoxicity. Toxicology in Vitro19, 991–999.
29.
ChenY., DongX-J., ZhangG-R., ShaoJ-Z. & XiangL-X. (2007). In vitro differentiation of mouse bone marrow stromal stem cells into hepatocytes induced by conditioned culture medium of hepatocytes. Journal of Cellular Biochemistry102, 52–63.
30.
MaurelP., DuretC., Gerbal-ChaloinS. & Daujat-ChavanieuM. (2005). Differentiation of hepatocyte-like cells from human embryonic stem cells and adult liver progenitors. [Abstracts of the Fifth World Congress on Alternatives & Animal Use in the Life Sciences.] ALTEX22 Special Issue, 291.
31.
Ben-PorathI. & WeinbergR.A. (2004). When cells get stressed: an integrative view of cellular senescence. Journal of Clinical Investigation113, 8–13.
de Julián-OrtizJ.V., García-DomenechG., GálvezJ. & PoglianiL. (2005). Predictability and prediction of lowest observed adverse effect levels in a structurally heterogeneous set of chemicals. SAR & QSAR in Environmental Research16, 263–272.
34.
García-DomenechG., de Julián-OrtizJ.V. & BesaluE. (2006). True prediction of lowest observed adverse effect levels. Molecular Diversity10, 159–168.
35.
GombarV.K., EnsleinK., HartJ.B., BlakeB.W. & BorgstedtH.H. (1991). Estimation of maximum tolerated dose for long-term bioassays from acute lethal dose and structure by QSAR. Risk Analysis11, 509–517.
36.
TilaouiL., SchilterB., TranL-A., MazzatortaP. & GrigorovM. (2007). Integrated computational methods for prediction of the lowest observable adverse effect level of food-borne molecules. QSAR & Combinatorial Science26, 102–108.
37.
VenkatapathyR., MoudgalC.J. & BruceR.M. (2004). Assessment of the oral rat chronic lowest observed adverse effect level model in TOPKAT, a QSAR software package for toxicity prediction. Journal of Chemical Information & Computer Sciences44, 1623–1629.
38.
BitschA., JacobiS., MelberC., WahnschaffeU., SimetskaN., & MangelsdorfI. (2006). REPDOSE: A database on repeated dose toxicity studies of commercial chemicals — A multifunctional tool. Regulatory Toxicology & Pharmacology46, 202–210.
39.
CombesR.D. (2008). In silico methods for toxicity prediction. In New Technologies for Toxicity Testing (ed. BhogalN., BallsM. & CombesR.D.), (in press). Georgetown, TX, USA: Landes Bioscience.
40.
DentM.P. (2007). Strengths and limitations of using repeat-dose toxicity studies to predict effects on fertility. Regulatory Toxicology & Pharmacology48, 241–258.
41.
CombesR., SchechtmanL., StokesW.S. & BlakeyD. (2002). The International Symposium on Regulatory Testing and Animal Welfare: Recommendations on best scientific practices for subchronic/ chronic toxicity and carcinogenicity testing. ILAR Journal43 Supplement, S112–S117.
42.
CombesR.D., GauntI. & BallsM. (2004). A scientific and animal welfare assessment of the OECD Health Effects Test Guidelines for the safety testing of chemicals under the European Union REACH system. ATLA32, 163–208.
43.
ShawR., FestingM.F.W., PeersI. & FurlongL. (2002). Use of factorial designs to optimize animal experiments and reduce animal use. ILAR Journal43, 223–232.
44.
FestingM.F.W., OverendP., DasR.G., BorjaM.C. & BerdoyM. (2002). Reducing the Use of Animals in Research Through Better Experimental Design, 118pp. London, UK:Royal Society of Medicine Press.
GrindonC., CombesR., CroninM.T.D., RobertsD.W. & GarrodJ.F. (2008). Integrated decision-tree testing strategies for acute systemic toxicity and toxicokinetics with respect to the requirements of the EU REACH legislation. ATLA36, 45–63.
51.
KhorT.O., IbrahimS. & KongA-N.T. (2006). Toxicogenomics in drug discovery and drug development: potential applications and future challenges. Pharmaceutical Research23, 1659–1664.
